Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Equity (2016 - 2025)

Historic Return on Equity for Myriad Genetics (MYGN) over the last 15 years, with Q3 2025 value amounting to 1.05%.

  • Myriad Genetics' Return on Equity fell 9000.0% to 1.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.05%, marking a year-over-year decrease of 9000.0%. This contributed to the annual value of 0.17% for FY2024, which is 1400.0% up from last year.
  • Per Myriad Genetics' latest filing, its Return on Equity stood at 1.05% for Q3 2025, which was down 9000.0% from 0.72% recorded in Q2 2025.
  • Myriad Genetics' 5-year Return on Equity high stood at 0.01% for Q1 2022, and its period low was 1.05% during Q3 2025.
  • Over the past 5 years, Myriad Genetics' median Return on Equity value was 0.17% (recorded in 2023), while the average stood at 0.24%.
  • Per our database at Business Quant, Myriad Genetics' Return on Equity soared by 2400bps in 2021 and then tumbled by -9000bps in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Return on Equity stood at 0.03% in 2021, then plummeted by -342bps to 0.12% in 2022, then tumbled by -189bps to 0.36% in 2023, then skyrocketed by 51bps to 0.18% in 2024, then plummeted by -492bps to 1.05% in 2025.
  • Its last three reported values are 1.05% in Q3 2025, 0.72% for Q2 2025, and 0.14% during Q1 2025.